Clinical Trial Update: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sequencing of osimertinib followed by chemotherapy in EGFR-mutated non-small cell lung cancer, focusing on a third-line osim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Mark Vincent | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING